Semaglutide

Research · Semaglutide

Overview

Semaglutide is a synthetic analog of endogenous GLP-1 with 94% structural homology to the native sequence. It incorporates a C-18 fatty diacid side chain enabling non-covalent albumin binding, extending systemic half-life to approximately 7 days. Widely used as a reference compound in GLP-1 receptor pharmacology research.

Mechanism of action

Activates the GLP-1 receptor, a G-protein-coupled receptor expressed in pancreatic beta cells, the central nervous system, and the gastrointestinal tract. Receptor activation stimulates glucose-dependent insulin secretion, suppresses glucagon release, and delays gastric emptying. The C-18 modification reduces renal clearance and confers resistance to proteolytic degradation.

Key research findings

1. 01

   Established as a reference agonist in GLP-1 receptor binding and signaling studies across cellular and animal models.

2. 02

   Preclinical rodent studies characterize dose-dependent effects on glucose tolerance and insulin secretion at pharmacologically relevant exposures.

3. 03

   Longitudinal cardiovascular outcomes trial data (SELECT, 2023) have characterized the compound's effects on major adverse cardiovascular events in participants with established cardiovascular disease.

4. 04

   Clinical pharmacokinetic studies document approximately 165-hour half-life, supporting once-weekly administration regimens in investigational use.

Published references

• Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

  Lincoff AM et al. — N Engl J Med, 2023 · PMID: 37952131

• The Discovery and Development of Liraglutide and Semaglutide

  Knudsen LB et al. — Front Endocrinol (Lausanne), 2019 · PMID: 31031702

The information above is derived from published preclinical and clinical research. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.